| Report ID | 278929 |
| Drug Identification Number | 02230640 |
| Brand name | TOBRAMYCIN INJECTION |
| Common or Proper name | Tobramycin Injection, USP 40 mg/mL, 30 mL Vial |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | TOBRAMYCIN |
| Strength(s) | 40MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 30 mL |
| ATC code | J01GB |
| ATC description | AMINOGLYCOSIDE ANTIBACTERIALS |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2026-03-31 |
| Actual start date | |
| Estimated end date | 2026-04-20 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2026-02-25 |
| Company comments | Fresenius Kabi Canada regrets to advise that, due to production delays we will encounter a backorder on our Tobramycin Injection, USP 40 mg/mL, 30 mL vial from April 1, 2026, until April 20, 2026. As previously communicated, all current inventory is short-dated and expires on March 31, 2026. Please continue to order the short-dated product while available. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2026-02-25 | French | Compare |
| v1 | 2026-02-25 | English | Compare |
Showing 1 to 2 of 2